O-I Glass Inc

UBS downgraded O-I Glass to Neutral from Buy and slashed its price target to a Street-low $6 from $11, sending the shares down as much as 5% before closing 0.9% lower. The downgrade centers on Europe, which UBS analyst Joshua Spector called "the main issue" after first-half 2026 EBIT in the region plunged to $6M from $158M a year earlier. Spector said the company is being severely affected by the spike in energy costs tied to the Iran conflict, and also faces weak competitiveness in Europe, two furnace outages, and lower cost savings targets that limit upside. He estimated EBITDA for 2026, 2027, and 2028 at 3% below, 2% below, and 1% above consensus, respectively, and noted volumes have declined for the last three years by an average 7%, with an additional 3%-5% modeled this year. Each percentage point of volume loss represents a $40M-$45M drop in pre-tax earnings, so a 2% volume decline next year would wipe out the modeled $100M cost savings benefit. O-I Glass shares have already plunged more than 60% year to date and are on track for their worst annual performance since 2000.

Schall, Brown & Schwartz LLP is investigating O-I Glass, Inc. for potential securities law violations. The investigation focuses on whether the company issued false or misleading statements or failed to disclose pertinent information to investors. O-I Glass reported its second quarter 2026 financial results on July 28, 2026, lowering its full-year adjusted earnings guidance and disappointing analysts. Operating profits in Europe fell to $6 million from $90 million in the prior-year period. Following the news, shares of O-I Glass dropped about 15% on July 29, 2026.

Levi & Korsinsky has announced a pending securities investigation into O-I Glass. The investigation concerns potentially materially false or misleading statements after the company's second quarter 2026 results missed consensus estimates, with revenue of $1.67 billion falling short of the expected $1.69 to $1.7 billion and adjusted earnings of $0.09 per share against estimates of around $0.29. O-I Glass also cut its full-year 2026 and 2027 guidance and disclosed an $873 million non-cash goodwill impairment, while Europe operating profit dropped to $6 million from $90 million in the prior-year period. Following the release, the stock fell approximately 15% on July 29, 2026. Investors who purchased O-I Glass stock and suffered losses may be eligible to participate in the investigation at no upfront cost.

Holzer & Holzer, LLC announced an investigation into whether O-I Glass, Inc. complied with federal securities laws. The investigation follows O-I's July 28, 2026 second-quarter report, which disclosed a loss of $6.33 per share, including an $873 million non-cash goodwill impairment charge and a $96 million increase to deferred tax valuation allowances, both related to Europe. The company's stock price dropped after the news. Shareholders who purchased O-I stock and suffered a loss are encouraged to contact the law firm.

O-I Glass reported a second quarter 2026 net loss of $972 million, driven largely by an $873 million goodwill impairment, alongside slightly lower revenue and an earnings miss. The company's share price fell 15% over the past day, leaving the year-to-date return down 49% and the five-year total shareholder return down 48%. The most followed valuation narrative on O-I Glass points to a fair value of $13.11 per share, suggesting the stock is undervalued relative to its last close of $7.70, with bulls citing significant cost reduction initiatives through the Fit to Win program that are expected to improve net margins and deliver higher future earnings. However, bears focus on the large goodwill hit and years of weak returns, and the bullish narrative could crack if demand weakness in Europe lingers or cost savings stall while energy and other input costs stay elevated.

Ford Motor, Teva Pharmaceutical, and Manhattan Associates were among the biggest stock gainers Wednesday, while Parsons led the losers after slashing its guidance. Ford shares rose 8% after the automaker beat Q2 revenue and adjusted EPS estimates and raised its full-year outlook, despite a net loss from one-time charges. Manhattan Associates jumped 25% on better-than-expected Q2 results and strong guidance, and Teva Pharmaceutical gained 10% after raising its 2026 innovative drug portfolio outlook. On the downside, Parsons tumbled 38% after cutting its FY2026 revenue and profit guidance, O-I Glass fell 19% on a Q2 earnings miss and lowered outlook, and Avis Budget Group slid 12% following a revenue and earnings miss.

IBM plunged 25% after issuing weaker-than-expected preliminary second-quarter earnings, expecting a profit of $2.93 per share excluding certain items versus the $3.01 per share analysts polled by FactSet had anticipated. Goldman Sachs jumped 7% after posting second-quarter earnings of $20.98 per share, well above the $14.48 LSEG consensus estimate, with revenue of $20.34 billion also topping the $16.13 billion expected. CleanSpark surged 11% after securing a 20-year data center lease in Georgia totaling $6.6 billion in contracted revenue. HCA Healthcare fell more than 7% after lowering its full-year earnings guidance to between $28.70 and $30.50 per share, down from a prior forecast of $29.10 to $31.50 per share, and also reduced the top end of its 2026 revenue outlook. JPMorgan Chase rose 2% after reporting second-quarter earnings of $6.14 per share on revenue of $58.02 billion, exceeding LSEG estimates of $5.85 per share on $50.19 billion in revenue. Bank of America added 2% after beating expectations with earnings of $1.21 per share on revenue of $31.7 billion, compared to the $1.13 per share and $30.72 billion consensus. Wells Fargo fell 3% despite posting earnings of $2.00 per share on revenue of $22.62 billion, above the $1.72 per share and $21.84 billion expected. Citigroup fell 5% even after logging its best quarterly revenue in a decade, with earnings of $3.15 per share on revenue of $24.77 billion, surpassing the $2.74 per share and $23.74 billion estimates. Apple dipped 1% after KeyBanc downgraded the stock to underweight from sector weight with a $250 price target, citing potential pressure from consumer spending pullbacks. O-I Glass slumped 8% after a double downgrade to underperform from buy at Bank of America, which pointed to a recent 20% rally, challenging glass demand, and other headwinds. LM Ericsson dropped 13% after reporting revenue of 52.70 billion Swedish kronor, missing the 53.94 billion consensus estimate, though adjusted gross margin of 48.4% topped the 47.8% expected. MBX Biosciences tumbled 8% after announcing CEO Kent Hawryluk stepped down effective immediately, to be replaced by Executive Chairman Steve Hoerter.